Search - tctmd.com

Displaying 1 - 20 of 222

Sort: Relevancy | Date

News Daily News

STAR Trial Gives Insight Into Two-Stage CTO PCI in Complex Patients

Yael L. Maxwell

December 05, 2025

News Conference News TCT 2025

At 3 Years, DCBs Still Less Safe Than DES in De Novo CAD: REC-CAGEFREE I

Yael L. Maxwell

November 07, 2025

News Conference News TCT 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

Todd Neale

November 03, 2025

News Conference News TCT 2025

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

Michael O'Riordan

October 26, 2025

News Opinion Editor's Corner TCT 2025

What’s Going to Be Hot at TCT 2025

Michael O'Riordan

October 09, 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2025

Michael O'Riordan

September 30, 2025

News Daily News

Coronary DCB Works Well in Multilayer In-Stent Restenosis: AGENT IDE Subanalysis

L.A. McKeown

August 12, 2025

News Industry News

Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary Vessels

June 12, 2025

News Conference News CRT 2025

AGENT IDE: DCB Performance for In-Stent Restenosis Lasts Out to 2 Years

L.A. McKeown

March 10, 2025

News Daily News

Top Coronary Artery Disease News in 2024

Michael O'Riordan

December 26, 2024

Presentation TCT 2024

Sirolimus- vs. Paclitaxel-Coated Balloons for the Treatment?of Coronary Artery Disease

Presenter: Pier Pasquale Leone

October 30, 2024

Presentation TCT 2024

Paclitaxel, Sirolimus, Biolimus: The Art of DCBs Selection

Presenter: Joanna Wykrzykowska

October 30, 2024

Presentation TCT 2024

TCT 500: Long-term Outcomes and Predictor of Target Lesion Revascularization the Patients After Treated With Paclitaxel Coated Balloon for Drug-Eluted Stent Restenosis

Presenter: Ikuta Akihiro

October 29, 2024

Presentation TCT 2024

TCT 501: Paclitaxel-Coated Balloon vs. Uncoated Balloon Angioplasty for Coronary In-Stent Restenosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Presenter: Dealla Samadi

October 29, 2024

Presentation TCT 2024

Head-to-Head Comparison of Sirolimus- Versus Paclitaxel-Coated Balloon Angioplasty in the Femoropopliteal Artery: The SIRONA Randomized Controlled Trial

Presenter: Ulf Teichgräber

October 29, 2024

Presentation TCT 2024

TCT 495: The Impact of Cutting Balloon Pre-Dilation on the Outcomes of Paclitaxel Drug-Coated Balloon Treatment for Coronary In-Stent Restenosis

Presenter: Yuanji Ma

October 29, 2024

Presentation TCT 2024

TCT 497: Sex-Specific Clinical Outcomes After Treatment of In-Stent Restenosis With the AGENT Paclitaxel-Coated Balloon: A Subgroup Analysis of the AGENT IDE Randomized Trial

Presenter: Jennifer Tremmel

October 29, 2024

Presentation TCT 2024

TCT 455: Quantitative Coronary Dissection Volume After Sirolimus or Paclitaxel Coated Balloon and Lumen Changes at 6 Months: Serial OCT Sub-study of TRANSFORM-I Trial

Presenter: Akihiro Tobe

October 29, 2024

Presentation TCT 2024

TCT 451: Plaque Changes and Vessel Remodeling After Balloon Angioplasty for De Novo Coronary Lesions Using Paclitaxel-Coated Balloons: A Serial IB-IVUS Study

Presenter: Shelby Kerr

October 29, 2024

News Conference News TCT 2024

DCB Outdo Noncompliant Balloons in Simple Bifurcation Side Branches: DCB-BIF

Caitlin E. Cox

October 28, 2024

Advertisement

STAR Trial Gives Insight Into Two-Stage CTO PCI in Complex Patients

At 3 Years, DCBs Still Less Safe Than DES in De Novo CAD: REC-CAGEFREE I

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

What’s Going to Be Hot at TCT 2025

TCTMD’s Top 10 Most Popular Stories for September 2025

Coronary DCB Works Well in Multilayer In-Stent Restenosis: AGENT IDE Subanalysis

Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary Vessels

AGENT IDE: DCB Performance for In-Stent Restenosis Lasts Out to 2 Years

Top Coronary Artery Disease News in 2024

Sirolimus- vs. Paclitaxel-Coated Balloons for the Treatment?of Coronary Artery Disease

Paclitaxel, Sirolimus, Biolimus: The Art of DCBs Selection

TCT 500: Long-term Outcomes and Predictor of Target Lesion Revascularization the Patients After Treated With Paclitaxel Coated Balloon for Drug-Eluted Stent Restenosis

TCT 501: Paclitaxel-Coated Balloon vs. Uncoated Balloon Angioplasty for Coronary In-Stent Restenosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Head-to-Head Comparison of Sirolimus- Versus Paclitaxel-Coated Balloon Angioplasty in the Femoropopliteal Artery: The SIRONA Randomized Controlled Trial

TCT 495: The Impact of Cutting Balloon Pre-Dilation on the Outcomes of Paclitaxel Drug-Coated Balloon Treatment for Coronary In-Stent Restenosis

TCT 497: Sex-Specific Clinical Outcomes After Treatment of In-Stent Restenosis With the AGENT Paclitaxel-Coated Balloon: A Subgroup Analysis of the AGENT IDE Randomized Trial

TCT 455: Quantitative Coronary Dissection Volume After Sirolimus or Paclitaxel Coated Balloon and Lumen Changes at 6 Months: Serial OCT Sub-study of TRANSFORM-I Trial

TCT 451: Plaque Changes and Vessel Remodeling After Balloon Angioplasty for De Novo Coronary Lesions Using Paclitaxel-Coated Balloons: A Serial IB-IVUS Study

DCB Outdo Noncompliant Balloons in Simple Bifurcation Side Branches: DCB-BIF

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content